Bronchiectasis is a chronic lung disease characterized by abnormal dilatation of the bronchi and bronchioles. Drugs used for treatment of bronchiectasis include antibiotics, bronchodilators, mucolytics, expectorants, and anti-inflammatory drugs. Antibiotics help in reducing infections while bronchodilators help in improving breathing. Drugs are preferred line of treatment along with other treatments such as physiotherapy and surgery.

The Bronchiectasis Drugs Market is estimated to be valued at US$ 303.8 Mn or Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends in the bronchiectasis drugs market is the rising research on advanced treatment options. Researchers are working on developing novel treatments such as precision therapies, gene therapies and stem cell therapies. For instance, scientists are exploring if gene therapy delivered through the airways could halt the progression of bronchiectasis. Researchers are also developing precision therapies that specifically target causal genetic mutations in certain bronchiectasis patients. Such advances are expected to bring more efficacious and targeted treatment options for bronchiectasis in the coming years.

Porter’s Analysis

Threat of new entrants: The threat of new entrants in the bronchiectasis drugs market is low as developing new drug is a complex, costly and time-consuming process which requires strong R&D capabilities. Bargaining power of buyers: The bargaining power of buyers in the market is moderate as there are some established branded drugs available and rising awareness.

Bargaining power of suppliers: The bargaining power of suppliers is low in the bronchiectasis drugs market as raw materials required for manufacturing drugs are commoditized and available off-the-shelf.

Threat of new substitutes: The threat of new substitutes is low as the disease has no alternative treatment available presently and new drug development requires huge investments and time.

Competitive rivalry: The competitive rivalry in the Global Bronchiectasis Drugs Market Size is high due to presence of many established players.

SWOT Analysis

Strength: Established distribution channel, strong R&D capabilities and portfolio of drugs. Weakness: High R&D costs associated with new drug development and patent cliff of major drugs.

Opportunity: High unmet medical needs, increasing prevalence of bronchiectasis and growth opportunities in emerging markets. Threats: Price erosion due to competition, regulatory challenges and reimbursement issues.

For More Insights, Read- https://www.feedsfloor.com/pharmaceuticals/rising-research-advanced-treatment-options-fuel-bronchiectasis-drugs-market-growth